352 related articles for article (PubMed ID: 14725581)
1. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors.
Kimmey MB; Lanas A
Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():60-5. PubMed ID: 14725581
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
3. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Naesdal J; Wilson I
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.
Dubois RW; Melmed GY; Henning JM; Laine L
Aliment Pharmacol Ther; 2004 Jan; 19(2):197-208. PubMed ID: 14723611
[TBL] [Abstract][Full Text] [Related]
5. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications.
Peura DA
Am J Med; 2004 Sep; 117 Suppl 5A():63S-71S. PubMed ID: 15478855
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
Ballinger A; Smith G
Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
[TBL] [Abstract][Full Text] [Related]
7. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Lanas A; Ferrandez A
Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
[TBL] [Abstract][Full Text] [Related]
8. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
Laine L
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.
Laine L; Wogen J; Yu H
Gastroenterology; 2003 Aug; 125(2):389-95. PubMed ID: 12891540
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Peura DA
Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
13. [Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors].
PrĂ³nai L
Orv Hetil; 2001 Sep; 142(35):1899-905. PubMed ID: 11601177
[TBL] [Abstract][Full Text] [Related]
14. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
Lehmann FS; Beglinger C
Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
[TBL] [Abstract][Full Text] [Related]
15. NSAIDs-induced gastrointestinal damage. Review.
Arroyo M; Lanas A
Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
[TBL] [Abstract][Full Text] [Related]
16. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.
Hawkey CJ; Langman MJ
Gut; 2003 Apr; 52(4):600-8. PubMed ID: 12631678
[TBL] [Abstract][Full Text] [Related]
17. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
James MW; Hawkey CJ
Br J Clin Pharmacol; 2003 Aug; 56(2):146-55. PubMed ID: 12895187
[TBL] [Abstract][Full Text] [Related]
18. COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Cryer B
Gastroenterology; 2004 Oct; 127(4):1256-8. PubMed ID: 15481002
[No Abstract] [Full Text] [Related]
19. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
20. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]